AndroBioSys, Inc.

AndroBioSys, Inc. (ABS) is a biotechnology company with focus on treating prostate disease. ABS is identifying specific targets in prostate tumors (e.g. prostate vasculature, tumor stem cells and androgen metabolism) which may be developed to improve prostate cancer treatment. Using unique human cell and tissue-based screening tools, the Company will identify candidate drugs and verify their specificity and activity.

ABS provides contract research services to pharmaceutical and biotechnology companies for further clinical evaluation of potential therapeutic agents. Androgen deprivation therapy is the most common systemic treatment for prostate cancer; the treatment is very effective for inducing remission but those remissions last only a few years. The primary goal of ABS is to pioneer new therapeutic approaches for advanced prostate cancer that will make therapy curative, not palliative. Prostate cancer is the most commonly diagnosed potentially life-threatening cancer in men in the United States. One in six men will be affected by this disease during their lifetime.

ABS was formed by two investigators at Roswell Park Cancer Institute (RPCI) in Buffalo, NY. The Company has exclusively licensed three technologies (in the form of pending patent applications) from RPCI. The Company's CEO has a very strong background in the commercialization of technologies and has over 15 years experience in the biotechnology industry with senior management positions at several start up companies.

ABS seeks $300,000 to accelerate its angiogenesis and anti-androgen programs and to validate the angiogenesis model. ABS will be poised to compete with contract research organizations such as MDS and Covance. With a lead compound discovered in the angiogenesis model, ABS will look to validate a prostate cancer angiogenesis target. With a lead drug candidate to a novel androgen target, ABS will look to commercialize a drug for a piece of the $4 billion plus market in anti-androgen therapy.